ArticleBMC public health2025
Impact of the COVID-19 pandemic on regional and national uptake of HIV testing services in Sierra Leone: a descriptive analysis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundA key milestone in the reduction of the global HIV burden is reaching the UNAIDS 95-95-95 target by 2025. The COVID-19 pandemic may have affected the ability of countries to achieve this target, but data to describe this impact is limited. This study assessed national HIV testing service uptake in Sierra Leone during three periods of the COVID-19 pandemic.
methodsWe conducted a retrospective cross-sectional study using secondary program data of all patients tested for HIV in all 16 districts of Sierra Leone. Data from March 2019 to February 2020 (pre-COVID-19); March 2020 to February 2021 (during COVID-19); and March 2021 to February 2022 (post-COVID-19) were extracted from DHIS-2 and descriptive analyses were performed using Stata (15.1, StataCorp LLC, College Station, TX).
resultsThe median number of HIV tests was 58,588 (IQR 54,232 to 62,077) in the pre-COVID phase, 55,141 (IQR 52,975 to 57,689) during the COVID-19 phase, and 74,954 (IQR 72,166 to 76,250) in the post-COVID phase. This shows that HIV testing rate decreased by 6.0% during the COVID-19 period and increased substantially by 36.0% in the post-COVID-19 period. Twice more women than men were tested for HIV across all periods-pre-COVID-19 (38,825 vs. 19,789), during COVID-19 (36,923 vs. 17,755), and post-COVID-19 (49,205 vs. 25,472) phases.
conclusionOur study shows that HIV testing was significantly disrupted during the COVID-19 pandemic but recovered quickly after the pandemic. These findings highlight that lessons learned from previous epidemics may influence adaptive strategies to maintain essential health services during public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.